Jussi J Saukkonen
Overview
Explore the profile of Jussi J Saukkonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson K, Schoenberg N, Cohn D, Crothers K, Fennelly K, Metlay J, et al.
Clin Infect Dis
. 2020 Sep;
73(7):e1467-e1475.
PMID: 32964218
Background: The American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) Community-acquired Pneumonia (CAP) guidelines were developed using systematic reviews to inform every recommendation, as suggested by the Institute of...
2.
Hedges K, Borisov A, Saukkonen J, Scott N, Hecker E, Bozeman L, et al.
Clin Trials
. 2019 Nov;
17(1):39-51.
PMID: 31690107
Background/aims: Efficient recruitment of eligible participants, optimizing time and sample size, is a crucial component in conducting a successful clinical trial. Inefficient participant recruitment can impede study progress, consume staff...
3.
Saukkonen J, Powell K, Jereb J
Am J Respir Crit Care Med
. 2012 Mar;
185(6):598-9.
PMID: 22422902
No abstract available.
4.
Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C, et al.
Am J Respir Crit Care Med
. 2006 Oct;
174(8):935-52.
PMID: 17021358
Drug-induced liver injury (DILI) is a problem of increasing significance, but has been a long-standing concern in the treatment of tuberculosis (TB) infection. The liver has a central role in...
5.
Shieh F, Snyder G, Horsburgh C, Bernardo J, Murphy C, Saukkonen J
Am J Respir Crit Care Med
. 2006 Jul;
174(6):717-21.
PMID: 16809632
Unlabelled: Treatment of latent tuberculosis (TB) infection (LTBI) is essential for the elimination of TB in the United States, but treatment is often not completed. Little is known about patients'...
6.
Jasmer R, Bozeman L, Schwartzman K, Cave M, Saukkonen J, Metchock B, et al.
Am J Respir Crit Care Med
. 2004 Oct;
170(12):1360-6.
PMID: 15477492
Recurrence of active tuberculosis after treatment can be due to relapse of infection with the same strain or reinfection with a new strain of Mycobacterium tuberculosis. The proportion of recurrent...
7.
Wilson K, Saukkonen J
J Intensive Care Med
. 2004 Aug;
19(4):183-93.
PMID: 15296619
Acute respiratory failure is a common complication of drug abuse. It is more likely to develop in the setting of chronic lung disease or debility in those with limited respiratory...
8.
Jasmer R, Snyder D, Saukkonen J, Hopewell P, Bernardo J, King M, et al.
Clin Infect Dis
. 2004 Jan;
38(3):363-9.
PMID: 14727206
Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection,...
9.
Jasmer R, Saukkonen J, Blumberg H, Daley C, Bernardo J, Vittinghoff E, et al.
Ann Intern Med
. 2002 Oct;
137(8):640-7.
PMID: 12379063
Background: Rifampin and pyrazinamide are recommended for treatment of latent tuberculosis infection in adults without HIV infection, but reports of severe hepatotoxicity have raised concerns about its safety. Clinical trials...
10.
Saukkonen J, Bazydlo B, Thomas M, Strieter R, Keane J, Kornfeld H
Infect Immun
. 2002 Mar;
70(4):1684-93.
PMID: 11895930
Chemokines (CK) are potent leukocyte activators and chemoattractants and aid in granuloma formation, functions critical for the immune response to Mycobacterium tuberculosis. We hypothesized that infection of alveolar macrophages (AM)...